Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...

Transcription activation of genes by estrogens is driven by enhancers, which are often located within the same Topologically Associating Domain (TAD) as non-targeted promoters. We investigated how ...

APRIL, a leading skincare and fragrance chain in Israel, secures exclusive rights to Escentric Molecules, a gender-free ...

JMP Securities initiated coverage of Instil Bio (TIL) with a Market Perform rating and no price target Instil Bio enters the :competitive ...

Click here for a full investment analysis of Cybin Inc., a speculative play on FDA approval for psychedelic-based treatments.

I believe in science.  The Earth is a sphere, orbiting the Sun, and the climate crisis is real, already destroying our economy.  Trump and his MAGA followers believe it is all a hoax.  Everything ...

One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets.

Pfizer's most advanced candidate, a molecule called danuglipron, has had a rough go at it, with middling efficacy and several ...

Needham & Company LLC reiterated their buy rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report issued on Wednesday morning, Benzinga reports. Needham & Company LLC ...

Fintel reports that on October 31, 2024, Jones Trading initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Buy ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and ...